Good Manufacturing Practice (GMP) panel sceptical over FDA's latest risk-based restructuring plans
This article was originally published in Clinica
The Food and Drug Administration's Center for Devices and Radiological Health last week unveiled the details of its risk-based plan for restructuring the workload of its over-taxed inspectors to a somewhat sceptical advisory panel on good manufacturing practices.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.